Press
Releases

Press Releases

December 11, 2020
Altimmune to Present at the 4th Annual NASH Summit 2020 Digital Conference
GAITHERSBURG, Md. , Dec. 11, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris , Chief Medical Officer of Altimmune will give an oral presentation on ALT-801, the Company’s novel GLP-1/Glucagon dual receptor
November 25, 2020
Altimmune Announces Submission of Investigational New Drug Application for AdCOVID™ a Single-dose Intranasal COVID-19 Vaccine; On Track to Commence Phase 1 Clinical Study in December
Simple, single-dose nasal spray offers greater ease and comfort of administration ;  positioning AdCOVID as a differentiated vaccine candidate for adults and children AdCOVID is capable of stimulating a n additional and specialized type of immunity – local nasal mucosal immunity – believed to be
November 16, 2020
Altimmune to Present at Upcoming Virtual Investor Conferences
GAITHERSBURG, Md. , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual
November 3, 2020
Altimmune to Announce Third Quarter 2020 Financial Results on November 10
GAITHERSBURG, Md. , Nov. 03, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 financial results on Tuesday, November 10, 2020 . Altimmune management will host a conference call for
October 15, 2020
Altimmune to Present at Two Upcoming Virtual Investor Conferences
GAITHERSBURG, Md. , Oct. 15, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual
 

Investor Contacts

Stacey Jurchison
Altimmune

Email: sjurchison@altimmune.com

Ashley Robinson
LifeSci Advisors, LLC

Email: arr@lifesciadvisors.com

 

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe